|
Patent landscape, scope, and claims: |
United States Drug Patent 7,067,551: Scope, Claims, and Landscape Analysis
What is United States Patent 7,067,551?
United States Patent 7,067,551, titled "Method for treating disorders involving inflammation and neuroprotection," was granted to Elan Pharma, Inc. on June 27, 2006. The patent describes a method for treating disorders that involve inflammation and neuroprotection. The core of the invention lies in administering a specific therapeutic agent or agents to individuals suffering from these conditions. The patent identifies various inflammatory and neurological disorders as targets for this method, aiming to reduce inflammation and protect neuronal cells from damage or degeneration.
The patent application was filed on October 31, 2002, and the earliest priority date extends back to October 31, 2001. This timeline places the invention within a period of significant research and development in neurodegenerative disease therapies and anti-inflammatory agents. The patent's expiration date is June 27, 2023, meaning it is no longer in force and is publicly available for use.
What are the Key Claims of Patent 7,067,551?
The claims of patent 7,067,551 define the legal boundaries of the invention. These claims are crucial for understanding what specific methods and compositions are protected by the patent.
Independent Claims:
- Claim 1: This is a method claim that describes treating a disorder involving inflammation and neurodegeneration. The method includes administering an effective amount of a composition comprising an amyloid beta peptide binding agent. The disorder is further characterized as one in which the administration of an amyloid beta peptide binding agent reduces inflammation and/or provides neuroprotection.
Dependent Claims:
Dependent claims further refine and limit the scope of the independent claims by adding specific conditions, components, or methods. For patent 7,067,551, dependent claims specify various aspects of the amyloid beta peptide binding agent and the disorders being treated.
- Claims 2-10: These claims build upon Claim 1, specifying types of amyloid beta peptide binding agents. This includes agents that bind to soluble amyloid beta peptides, amyloid beta peptides in aggregated form, and specifically oligomeric amyloid beta peptides. The claims also detail the nature of the binding agent, such as an antibody, a fragment of an antibody, or a peptidomimetic.
- Claims 11-20: These claims focus on the specific disorders being treated. They include neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Down's syndrome, and amyotrophic lateral sclerosis (ALS). The claims also encompass other inflammatory conditions with a neuroprotective component.
- Claims 21-30: These claims detail the administration of the therapeutic agent. This includes specific routes of administration (e.g., intravenous, subcutaneous, intramuscular), dosage regimens, and the co-administration with other therapeutic agents.
The detailed claims define a method of treatment for specific neurological and inflammatory conditions using agents designed to target and bind to amyloid beta peptides, with the explicit aim of reducing inflammation and providing neuroprotection.
What is the Therapeutic Target and Mechanism of Action?
The patent 7,067,551 centers on targeting amyloid beta (Aβ) peptides, which are known to accumulate in the brain and are implicated in the pathogenesis of Alzheimer's disease and other neurodegenerative conditions. The proposed mechanism of action involves the binding of an amyloid beta peptide binding agent to these peptides.
Key Aspects of the Therapeutic Target and Mechanism:
- Amyloid Beta Peptides: The primary target is the amyloid beta peptide. The patent acknowledges that Aβ can exist in various forms, including soluble monomers, oligomers, protofibrils, and fibrils. Different claims within the patent specify binding to different forms of Aβ, suggesting a broad approach to targeting.
- Inflammation and Neurodegeneration: The patent asserts that Aβ accumulation contributes to both inflammatory processes within the central nervous system and neuronal degeneration. By binding to Aβ, the therapeutic agent is intended to disrupt these pathological cascades.
- Binding Agent: The patent protects methods that utilize an "amyloid beta peptide binding agent." This agent's function is to interact with and sequester Aβ peptides.
- Neuroprotection: The binding of the agent to Aβ is posited to reduce inflammation and/or provide neuroprotection. This neuroprotection is likely achieved by preventing Aβ-induced toxicity, reducing inflammatory mediator release, or promoting neuronal survival pathways.
- Oligomeric Aβ: Several claims specifically highlight the importance of targeting soluble oligomeric forms of Aβ. Oligomers are increasingly recognized as particularly toxic species that precede fibril formation and plaque deposition in Alzheimer's disease. Binding to these species is proposed as a key intervention point.
The mechanism implies that by neutralizing or clearing Aβ peptides, the inflammatory response associated with their presence is mitigated, and neuronal cells are shielded from their toxic effects, thereby offering therapeutic benefit in neurodegenerative disorders.
What are the Primary Disorders Targeted by Patent 7,067,551?
Patent 7,067,551 outlines a therapeutic strategy for a range of neurological and inflammatory disorders where amyloid beta peptide involvement and associated inflammation are significant pathological factors.
Key Targeted Disorders:
- Alzheimer's Disease: This is a primary focus, given the well-established role of amyloid beta plaque deposition in its pathology. The method aims to reduce Aβ burden, inflammation, and neurodegeneration characteristic of this disease.
- Parkinson's Disease: While alpha-synuclein is the primary protein aggregate in Parkinson's, there is growing evidence linking Aβ pathology and neuroinflammation to the disease process.
- Huntington's Disease: This is a hereditary neurodegenerative disorder. While the primary genetic defect involves the huntingtin protein, neuroinflammation is a significant contributor to neuronal dysfunction and death.
- Down's Syndrome: Individuals with Down's syndrome have an extra copy of chromosome 21, which carries the gene for amyloid precursor protein (APP). This leads to increased Aβ production and a high incidence of Alzheimer's-like pathology in adulthood.
- Amyotrophic Lateral Sclerosis (ALS): Also known as Lou Gehrig's disease, ALS is a progressive neurodegenerative disease affecting nerve cells in the brain and spinal cord. Neuroinflammation and protein aggregation, including Aβ in some cases, are implicated.
- Other Neurodegenerative Disorders: The patent broadly covers disorders involving inflammation and neurodegeneration, suggesting applicability to other conditions where these two processes are central.
- Inflammatory Conditions with Neuroprotective Component: The wording "disorders involving inflammation and neuroprotection" indicates that conditions that are primarily inflammatory but also lead to neurological damage are within the scope.
The patent's broad scope in targeting disorders reflects the understanding that amyloid beta and neuroinflammation are not confined solely to Alzheimer's disease but are emerging as critical factors in a wider spectrum of neurological ailments.
What is the Patent Landscape for Amyloid Beta Targeting Therapies?
The patent landscape for therapies targeting amyloid beta (Aβ) is extensive and competitive, reflecting the significant clinical and commercial interest in treating Alzheimer's disease and related disorders. Patent 7,067,551, while expired, contributes to this historical landscape.
Key Characteristics of the Aβ Patent Landscape:
- Vast Number of Patents: Thousands of patents have been issued globally covering various aspects of Aβ biology, detection, and therapeutic intervention. These include patents on Aβ peptides themselves, APP processing, Aβ aggregation inhibitors, antibodies targeting Aβ, small molecules that modulate Aβ levels, and methods of treatment.
- Dominance of Antibody Therapies: A significant portion of the patent activity and clinical development has focused on monoclonal antibodies designed to bind to and clear Aβ. Examples include aducanumab, lecanemab, and donanemab, which have received regulatory approvals or are in late-stage trials. Patents covering these antibodies are critical assets for the developing companies.
- Small Molecule Inhibitors: Patents also exist for small molecules that aim to inhibit Aβ production (e.g., by targeting BACE1 or gamma-secretase), prevent Aβ aggregation, or promote Aβ clearance through other mechanisms.
- Method of Treatment Patents: Patents like 7,067,551 that claim methods of treating specific diseases by administering an Aβ targeting agent are also common. These can provide broad protection for therapeutic applications even if the specific drug molecule itself is not claimed.
- Focus on Specific Aβ Species: As research has progressed, patents have become more specific, targeting particular forms of Aβ, such as soluble oligomers or protofibrils, which are believed to be more pathogenic than mature plaques.
- Geographic Distribution: The patent landscape is global, with major patent offices in the US, Europe, Japan, and China being key filing locations.
- Expirations and Generic Competition: As older patents expire, such as patent 7,067,551, the underlying technologies or methods become available for broader use, potentially enabling generic or biosimilar development, albeit with significant scientific and regulatory hurdles for complex biologics.
- Ongoing Innovation: Despite the maturity of some aspects, the field continues to see innovation. Newer patents may cover novel targets within the Aβ pathway, improved delivery mechanisms, combination therapies, or diagnostic tools linked to therapeutic response.
The expiry of patent 7,067,551 means that the specific method claims it covered are now in the public domain. Companies developing Aβ-targeting therapies will need to navigate a complex web of existing and pending patents, focusing on novel aspects of drug discovery, formulation, and therapeutic application to secure their intellectual property.
What are the Implications of Patent 7,067,551's Expiration?
The expiration of United States Patent 7,067,551 on June 27, 2023, has several implications for the pharmaceutical industry, particularly for companies involved in the development of treatments for neurodegenerative and inflammatory disorders.
Key Implications:
- Public Domain Status: The method claims described in patent 7,067,551 are now in the public domain. This means that any entity can practice the claimed methods without infringing on this specific patent. This could potentially lower the barrier for generic manufacturers or academic researchers exploring similar therapeutic approaches, although patentability of new formulations or specific drug applications would still be subject to existing prior art.
- Reduced Licensing Costs: For companies whose current or future drug candidates employ the therapeutic method described in patent 7,067,551, the expiration eliminates any ongoing royalty payments or licensing fees that might have been associated with its use.
- Freedom to Operate: The expiration expands the freedom to operate for researchers and developers in the field of amyloid beta targeting therapies. It removes one layer of intellectual property restriction that previously existed for methods involving administering amyloid beta peptide binding agents for the specified therapeutic purposes.
- Impact on Existing Therapies: If any currently marketed drugs or late-stage clinical candidates were practicing the exact method claimed in patent 7,067,551, their market exclusivity based on this patent is now removed. However, such drugs are likely protected by other, more specific patents related to the drug molecule itself, its formulation, or other methods of use.
- Historical Context: The patent now serves as a historical document, illustrating earlier approaches and claims in the field of Aβ therapeutics. It contributes to the body of knowledge and prior art that future patent applications will be assessed against.
- Focus on Novelty: With older, broader method patents expiring, the emphasis in new patent filings and commercial strategies will increasingly shift towards novel drug compounds, unique formulations, specific delivery systems, and innovative therapeutic combinations that offer clear advantages over existing treatments or the now-public domain methods.
- Potential for New Entrants: While developing Aβ-targeting therapies is complex and capital-intensive, the expiration of patents like 7,067,551 might marginally encourage new entrants or smaller research groups to investigate these therapeutic avenues, provided they can establish their own intellectual property around novel aspects.
In summary, patent 7,067,551's expiration removes a specific legal constraint on practicing its claimed method, offering greater freedom and potentially reducing costs for those working in the Aβ therapeutic space. However, the broader patent landscape remains active, requiring careful navigation of other intellectual property rights.
Key Takeaways
- United States Patent 7,067,551, granted in 2006 to Elan Pharma, Inc., described a method for treating inflammation and neuroprotection disorders by administering amyloid beta peptide binding agents.
- The patent's claims protected methods of treating specific neurodegenerative diseases, including Alzheimer's, Parkinson's, and ALS, by targeting amyloid beta peptides to reduce inflammation and provide neuroprotection.
- The patent expired on June 27, 2023, rendering its method claims publicly available for use without infringement.
- The expiration removes an intellectual property barrier, potentially reducing licensing costs and expanding freedom to operate for researchers and developers in the amyloid beta therapeutics field.
- The broader patent landscape for amyloid beta targeting therapies remains extensive, with ongoing innovation in antibody therapies, small molecules, and novel delivery systems, requiring careful IP navigation.
Frequently Asked Questions
- What specific types of amyloid beta peptide binding agents were claimed in patent 7,067,551?
The patent claimed agents that bind to soluble amyloid beta peptides, aggregated amyloid beta peptides, and specifically oligomeric amyloid beta peptides, including antibodies, antibody fragments, and peptidomimetics.
- Can companies now freely develop and sell drugs that use the method described in patent 7,067,551?
While the specific method claims are in the public domain, companies must ensure their drug products and specific therapeutic approaches do not infringe on other existing patents related to drug molecules, formulations, or other methods of use.
- Does the expiration of patent 7,067,551 mean there will be immediate generic versions of amyloid beta therapies?
No, the expiration of this specific method patent does not automatically lead to generic versions of complex biological therapies. Generic drug development, especially for biologics, involves significant scientific, regulatory, and manufacturing challenges, and is typically limited by patents on the drug substance itself and its manufacturing process.
- What is the significance of targeting oligomeric amyloid beta peptides as mentioned in the patent?
Targeting oligomeric amyloid beta peptides is considered significant because these soluble aggregates are believed to be more neurotoxic and to precede the formation of insoluble amyloid plaques, making them a critical target for early intervention in diseases like Alzheimer's.
- How does the expiration of patent 7,067,551 affect ongoing research in Alzheimer's disease therapeutics?
The expiration provides researchers with greater freedom to explore and utilize the general therapeutic approach of targeting amyloid beta peptides for neuroprotection and anti-inflammation without licensing this specific method. This can encourage broader academic and early-stage industrial research into this therapeutic strategy.
Citations
[1] Elan Pharma, Inc. (2006). Method for treating disorders involving inflammation and neuroprotection. U.S. Patent 7,067,551. Washington, DC: U.S. Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
